<DOC>
	<DOCNO>NCT02775916</DOCNO>
	<brief_summary>This Study design evaluate safety , tolerability , pharmacokinetics preliminary therapeutic efficacy oral administration CDZ173 , selective PI3K Delta inhibitor , 12 week , patient primary Sjögren 's syndrome . Data study provide basis development compound treatment primary Sjögren 's syndrome .</brief_summary>
	<brief_title>Safety , Pharmacokinetics , Preliminary Efficacy Study CDZ173 Patients With Primary Sjögren 's Syndrome</brief_title>
	<detailed_description>This study design evaluate safety , tolerability , pharmacokinetics preliminary therapeutic efficacy oral administration CDZ173 , selective PI3K delta inhibitor , 12 week , patient primary Sjögren 's syndrome . Data study provide basis development compound treatment primary Sjögren 's syndrome .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<criteria>Diagnosis primary Sjögren 's syndrome ( pSS ) ESSDAI score ≥ 6 ; Secondary Sjögren 's syndrome Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>